SI21702A - Preparation of amorphous form of tamsulosin - Google Patents

Preparation of amorphous form of tamsulosin Download PDF

Info

Publication number: SI21702A
Authority: SI; Slovenia
Prior art keywords: tamsulosin hydrochloride; tamsulosin; amorphous form; hydrochloride; preparation
Prior art date: 2004-01-29

Application number

SI200400032A

Other languages

English (en)

Slovenian (sl)

Inventor

Zoran Ham

Original Assignee

Lek Farmacevtska Druzba Dd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-29

Filing date

2004-01-29

Publication date

2005-08-31

2004-01-29 Application filed by Lek Farmacevtska Druzba Dd filed Critical Lek Farmacevtska Druzba Dd

2004-01-29 Priority to SI200400032A priority Critical patent/SI21702A/sl

2005-01-28 Priority to PCT/EP2005/000875 priority patent/WO2005075416A1/en

2005-01-28 Priority to US10/587,376 priority patent/US20070161709A1/en

2005-01-28 Priority to SI200530764T priority patent/SI1713769T1/sl

2005-01-28 Priority to AT05715224T priority patent/ATE434604T1/de

2005-01-28 Priority to EP05715224A priority patent/EP1713769B1/de

2005-01-28 Priority to DE602005015083T priority patent/DE602005015083D1/de

2005-08-31 Publication of SI21702A publication Critical patent/SI21702A/sl

Links

238000002360 preparation method Methods 0.000 title claims abstract description 13
DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 title claims description 14
229960002613 tamsulosin Drugs 0.000 title description 13
ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 claims abstract description 37
229960003198 tamsulosin hydrochloride Drugs 0.000 claims abstract description 36
238000000034 method Methods 0.000 claims abstract description 14
238000004108 freeze drying Methods 0.000 claims abstract description 6
239000013543 active substance Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 3
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
238000001694 spray drying Methods 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000002844 melting Methods 0.000 description 8
230000008018 melting Effects 0.000 description 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000843 powder Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000002329 infrared spectrum Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000004566 IR spectroscopy Methods 0.000 description 3
238000007707 calorimetry Methods 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000000634 powder X-ray diffraction Methods 0.000 description 3
239000004480 active ingredient Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000001938 differential scanning calorimetry curve Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000011197 physicochemical method Methods 0.000 description 2
ODLMAHJVESYWTB-UHFFFAOYSA-N propylbenzene Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 2
238000001757 thermogravimetry curve Methods 0.000 description 2
IOYHGBZPUZBUTJ-UHFFFAOYSA-N 1-(2-bromoethoxy)-2-ethoxybenzene Chemical compound CCOC1=CC=CC=C1OCCBr IOYHGBZPUZBUTJ-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
DRHKJLXJIQTDTD-UHFFFAOYSA-N 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide Chemical compound CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-UHFFFAOYSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000010926 purge Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)

SI200400032A 2004-01-29 2004-01-29 Preparation of amorphous form of tamsulosin SI21702A (en)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
SI200400032A SI21702A (en)	2004-01-29	2004-01-29	Preparation of amorphous form of tamsulosin
PCT/EP2005/000875 WO2005075416A1 (en)	2004-01-29	2005-01-28	Amorphous tamsulosin hydrochloride
US10/587,376 US20070161709A1 (en)	2004-01-29	2005-01-28	Amorphous tamsulosin hydrochloride
SI200530764T SI1713769T1 (sl)	2004-01-29	2005-01-28	Priprava amorfne oblike tamsulozina
AT05715224T ATE434604T1 (de)	2004-01-29	2005-01-28	Amorphes tamsulosin-hydrochlorid
EP05715224A EP1713769B1 (de)	2004-01-29	2005-01-28	Amorphes tamsulosin-hydrochlorid
DE602005015083T DE602005015083D1 (de)	2004-01-29	2005-01-28	Amorphes tamsulosin-hydrochlorid

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SI200400032A SI21702A (en)	2004-01-29	2004-01-29	Preparation of amorphous form of tamsulosin

Publications (1)

Publication Number	Publication Date
SI21702A true SI21702A (en)	2005-08-31

Family

ID=34836935

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200400032A SI21702A (en)	2004-01-29	2004-01-29	Preparation of amorphous form of tamsulosin
SI200530764T SI1713769T1 (sl)	2004-01-29	2005-01-28	Priprava amorfne oblike tamsulozina

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200530764T SI1713769T1 (sl)	2004-01-29	2005-01-28	Priprava amorfne oblike tamsulozina

Country Status (6)

Country	Link
US (1)	US20070161709A1 (de)
EP (1)	EP1713769B1 (de)
AT (1)	ATE434604T1 (de)
DE (1)	DE602005015083D1 (de)
SI (2)	SI21702A (de)
WO (1)	WO2005075416A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH066565B2 (ja) *	1986-07-21	1994-01-26	山之内製薬株式会社	光学活性なベンゼンスルホンアミド誘導体の製造法
US6395300B1 (en) *	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US6835853B2 (en) *	2001-10-31	2004-12-28	Synthon Bv	Process for resolution of tamsulosin and compounds, compositions, and processes associated therewith
JP2005512997A (ja) *	2001-11-07	2005-05-12	シントン・ベスローテン・フェンノートシャップ	タムスロシン錠

2004
- 2004-01-29 SI SI200400032A patent/SI21702A/sl not_active IP Right Cessation
2005
- 2005-01-28 AT AT05715224T patent/ATE434604T1/de not_active IP Right Cessation
- 2005-01-28 WO PCT/EP2005/000875 patent/WO2005075416A1/en not_active Ceased
- 2005-01-28 SI SI200530764T patent/SI1713769T1/sl unknown
- 2005-01-28 US US10/587,376 patent/US20070161709A1/en not_active Abandoned
- 2005-01-28 EP EP05715224A patent/EP1713769B1/de not_active Expired - Lifetime
- 2005-01-28 DE DE602005015083T patent/DE602005015083D1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ATE434604T1 (de)	2009-07-15
DE602005015083D1 (de)	2009-08-06
US20070161709A1 (en)	2007-07-12
EP1713769B1 (de)	2009-06-24
SI1713769T1 (sl)	2009-10-31
EP1713769A1 (de)	2006-10-25
WO2005075416A1 (en)	2005-08-18

Similar Documents

Publication	Publication Date	Title
RU2733412C2 (ru)	2020-10-01	Поликристаллическая форма свободного основания или соли присоединения кислоты ингибитора egfr, способ её получения и применение
Yan et al.	2015	Thermodynamics and preliminary pharmaceutical characterization of a melatonin–pimelic acid cocrystal prepared by a melt crystallization method
JP2017521438A (ja)	2017-08-03	ｃ−Ｍｅｔ阻害剤の結晶性フリー塩基またはそれらの結晶性酸性塩、およびそれらの製造方法および用途
WO2017008773A1 (en)	2017-01-19	Crystalline forms of obeticholic acid
CN110650963A (zh)	2020-01-03	(S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂*-9-基)氨基)丙酰胺的多晶型物和固体形式及其制备方法
EP3256474B1 (de)	2019-09-25	Ibrutinib-sulfatsalz
WO2016127963A1 (en)	2016-08-18	Solid forms of palbociclib salts
TWI449705B (zh)	2014-08-21	１１－（２－吡咯啶－１－基－乙氧基）－１４，１９－二－５，７，２６－三氮雜－四環〔１９．３．１．１（２，６）．１（８，１２）〕二十七碳－１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３－十烯檸檬酸鹽
JP7152122B2 (ja)	2022-10-12	エダラボン塩
TWI457342B (zh)	2014-10-21	１１－（２－吡咯啶－１－基－乙氧基）－１４，１９－二－５，７，２６－三氮雜－四環〔１９．３．１．１（２，６）．１（８，１２）〕二十七碳－１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３－十烯順丁烯二酸鹽
SI21702A (en)	2005-08-31	Preparation of amorphous form of tamsulosin
WO2016058564A1 (en)	2016-04-21	Salts of bedaquiline
CN114026088A (zh)	2022-02-08	Jak2抑制剂的结晶形式
Chen et al.	2022	Pharmaceutical cocrystals of nomegestrol acetate with superior dissolution
SK9752000A3 (en)	2001-02-12	Thermodynamically stable form of (r)-3-[ [(4-fluorophenyl) sulphonyl]amino]-1,2,3,4-tetrahydro-9h-carbazole-9-propanoic acid (ramatroban)
SI21616A (sl)	2005-04-30	Nove kristalne oblike karvedilola
EP2705034A1 (de)	2014-03-12	Kristallines natriumsalz eines hiv-integrase-inhibitors
US20260109685A1 (en)	2026-04-23	Solid forms of pralsetinib
TWI922473B (zh)	2026-04-21	普拉替尼之固體形式
JP2004501902A (ja)	2004-01-22	Ｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）−キナゾリン−６−イル］−アクリルアミドジヒドロクロリドの多形性形態／水和物
WO2016127962A1 (en)	2016-08-18	An amorphous solid form of suvorexant with sulphuric acid
EP3372592A1 (de)	2018-09-12	Feste formen von lesinurad aminsälze
HK40090302A (zh)	2023-11-03	普拉替尼的固体形式
HK40103083A (zh)	2024-06-21	(3r)-n-[2-氰基-4-氟-3-(3-甲基-4-氧代-喹唑啉-6-基)氧基-苯基]-3-氟-吡咯烷-1-磺酰胺的新颖固体形式
CN101437793B (zh)	2012-08-22	结晶的（3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）哌嗪-1-基]甲酮磷酸盐

Legal Events

Date	Code	Title	Description
2005-10-31	OO00	Grant of patent	Effective date: 20040629
2013-10-30	KO00	Lapse of patent	Effective date: 20130903